Endo makes investments in game-changing early stage companies improving outcomes for large patient populations affected by various chronic diseases. Endo is backed by a group of mission-oriented investors and was created in response to a deficit of early-stage capital focused on companies impacting diabetes and other major global health issues.
Eric Edidin formed Endo Investors in 2013, soon after his then toddler daughter was diagnosed with type-1 diabetes. Endo portfolio companies have made numerous cutting edge break-throughs for the patient populations they serve while simultaneously focusing on strong returns for their investors.
Mr. Edidin is also president of Three B Holdings, a private family investment company, and co-founded Archer Capital Management an institutional asset management firm in 2006. Previously, he was a portfolio manager and co-head of credit investments at York Capital Management, a member of Morgan Stanley Capital Partners global private equity investment team and Blackstone Group’s restructuring advisory team.
Mr. Edidin is an executive board member of the JDRF of Los Angeles, and member of the investment committee of the Jewish Communal Fund of NY and the Jewish Federation of Los Angeles.
Eric holds a B.B.A. degree with highest distinction from the University of Michigan, and an M.B.A from Harvard Business School.
Capillary Biomedical aims to simplify insulin infusions to improve the quality of life for people with diabetes. It first product, the SteadiSet™ infusion set featuring SteadiFlow™ technology, is designed to improve the comfort, reliability and predictability of pump therapy.Visit
Diasome is developing hepatocyte directed vesicle (HDV) technology to reduce the incidence of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. HDV technology is being developed as an additive to all forms of insulin to improve its safety and efficacy by restoring the liver’s natural role in blood glucose control.Visit
Locemia Solutions has developed a needle-free glucagon rescue treatment for severe hypoglycemia called Baqsimi. The worldwide product rights were sold to Eli Lilly and company (NYSE:LLY) in 2015. Baqsimi was successfully launched commercially in 2019.Visit
Mellitus Health’s Insulin Insights™ software makes precision insulin dosing recommendations in seconds, enabling clinicians to optimize insulin regimens—reducing blood glucose, complications, and healthcare costsVisit